{
    "xml": "<topic id=\"PHP1402\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/naftidrofuryl-oxalate\" basename=\"naftidrofuryl-oxalate\" title=\"NAFTIDROFURYL OXALATE\">\n<title>NAFTIDROFURYL OXALATE</title>\n<body>\n<data name=\"vtmid\">350627007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_990264817\" title=\"5HT&#8322; receptor antagonists\">5HT&#8322; receptor antagonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP70153\" outputclass=\"indicationsAndDose\" rev=\"1.13\" parent=\"/drugs/naftidrofuryl-oxalate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Peripheral vascular disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8211;200&#8239;mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Cerebral vascular disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>100&#8239;mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70070\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/naftidrofuryl-oxalate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Epigastric pain</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69980\" outputclass=\"nationalFunding\" rev=\"1.17\" parent=\"/drugs/naftidrofuryl-oxalate\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA223</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011)</p>\r\n<p>Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in patients with peripheral arterial disease in whom vasodilator therapy is considered appropriate.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA223\">www.nice.org.uk/TA223</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1402-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/naftidrofuryl-oxalate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74722\" title=\"Capsule\" namespace=\"/drugs/naftidrofuryl-oxalate/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78175\" namespace=\"/treatment-summaries/peripheral-vascular-disease\" title=\"Peripheral vascular disease\" count=\"3\" rel=\"backlink\">Peripheral vascular disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74722\" namespace=\"/drugs/naftidrofuryl-oxalate/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP1402",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/naftidrofuryl-oxalate",
    "basename": "naftidrofuryl-oxalate",
    "title": "NAFTIDROFURYL OXALATE",
    "vtmid": "350627007",
    "drugClassification": [
        "5HT&#8322; receptor antagonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Peripheral vascular disease",
                        "html": "Peripheral vascular disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "100&#8211;200 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.",
                        "html": "<p>100&#8211;200&#8239;mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Cerebral vascular disease",
                        "html": "Cerebral vascular disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "100 mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.",
                        "html": "<p>100&#8239;mg 3 times a day, patients taking naftidrofuryl should be assessed for improvement after 3&#8211;6 months.</p>"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Epigastric pain",
                        "html": "Epigastric pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA223",
                        "label": "www.nice.org.uk/TA223"
                    }
                ],
                "fundingIdentifier": "NICE TA223",
                "textContent": "Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011) Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in patients with peripheral arterial disease in whom vasodilator therapy is considered appropriate.\n\nwww.nice.org.uk/TA223",
                "html": "<p outputclass=\"title\">Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (May 2011)</p> <p>Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in patients with peripheral arterial disease in whom vasodilator therapy is considered appropriate.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA223\">www.nice.org.uk/TA223</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74722",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78175",
                "label": "Peripheral vascular disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74722",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}